Alpha-Lipoic Acid (ALA) for ALS
Also known as: ALA, Thioctic acid, R-lipoic acid
ALA's mitochondrial antioxidant and metal-chelating properties target oxidative damage in ALS motor neurons.
Mechanism of Action
ALA regenerates endogenous antioxidants (glutathione, vitamins C/E), chelates redox-active metals (iron, copper), and directly scavenges ROS within mitochondria. As a cofactor for pyruvate dehydrogenase, it enhances mitochondrial energy production in energy-starved motor neurons.
General mechanism: Universal antioxidant and mitochondrial cofactor. Regenerates other antioxidants, chelates metals, enhances pyruvate dehydrogenase activity.
Current Evidence
Small pilot studies show safety and trends toward slower ALSFRS-R decline. Combination with ALCAR studied. Results mixed but mechanism sound.
Clinical Status: Phase II pilot trials. Available as supplement.
Safety Profile
Very safe orally. IV use requires medical supervision. Hypoglycemia risk in diabetics. Rare: autoimmune insulin syndrome in susceptible individuals.
Key Research Questions
- Does R-lipoic acid outperform racemic ALA for neuroprotection?
- Can ALA chelation benefit SOD1-ALS patients with copper dysregulation?